Assertion: ace inhibitor | /r/HasProperty | arb
Facets:
Source sentences:
text: Based on the 2013 Kidney Disease Improving Global Outcomes (KDIGO) guidelines, the use of an ACE inhibitor or an angiotensin receptor blocker (ARB) is recommended in patients with proteinuric CKD to prevent progression of CKD.
text: When we restricted the analysis to patients who survived at least 90 days after initial MDS assessment (n = 13,270), the rate of functional decline was still significantly attenuated by treatment with an ACE inhibitor (RR, 0.86; 95% CI, 0.79-0.94).
text: The triple combination of an ACE-inhibitor, ARB, and a mineralocorticoid receptor antagonist or other potassium-sparing diuretic is not recommended.
text: The triple combination of an ACE-inhibitor, ARB, and a mineralocorticoid receptor antagonist or other potassium-sparing diuretic is not recommended.
text: The authors also note that their findings have "important implications" for four ongoing randomized trials of ACE inhibitors/ARBs in COVID-19, "as none of them align with the observations of our study.
text: The authors also note that their findings have "important implications" for four ongoing randomized trials of ACE inhibitors/ARBs in COVID-19, "as none of them align with the observations of our study.
text: Conclusion: continue ACE inhibitors/ARBs unless otherwise indicated
text: ACE inhibitors/ARBs to avoid with Entresto
text: Hypertension expert Franz Messerli, MD, told Medscape Medical News that ACE2 could be upregulated with ACE inhibitors/ARBs and there is speculation that this could increase infectivity with COVID-19,
text: but we don’t know how ACE inhibitors/ARBs affect ACE2 in humans.
text: ACE inhibitors/ARBs are also the mainstay of treatment in heart failure, chronic kidney disease, and diabetic nephropathy.
text: Additionally, there were viewpoints that were noting the potential harm of ACE inhibitors/ARBs that were published previously and we wanted to provide a more balanced perspective.
text: The American College of Cardiology/American Heart Association guidelines recommend that treatment of patients with hypertension who have had a myocardial infarction include an ACE inhibitor, an ARB (for patients intolerant of ACE inhibitors), a beta blocker, and an aldosterone antagonist (for patients with symptomatic heart failure without hyperkalemia or significant renal
text: The new guidelines recommend either an ACE inhibitor, an ARB, oran ARNI (e.g., Entresto) for patients with chronic HFrEF, but not in combination (Table 1, prepared by ISMP).
text: Indeed, overly vigorous inhibition of neuro-hormonal activation during heart failure, by simultaneous treatment with an ACE inhibitor, an ARB and a β-blocker was associated with excess mortality in the Valsartan Heart Failure Trial (Val-HeFT)90.